Literature DB >> 26138174

To see or not to see: An eye opening optical coherence tomography.

Ramesh Daggubati1, Ramya Suryadevara2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26138174      PMCID: PMC4495584          DOI: 10.1016/j.ihj.2015.05.006

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


× No keyword cloud information.
  4 in total

1.  Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials: insight from over 8.1 million percutaneous coronary interventions.

Authors:  Sripal Bangalore; Navdeep Gupta; Philippe Généreux; Yu Guo; Samir Pancholy; Frederick Feit
Journal:  Int J Cardiol       Date:  2015-01-27       Impact factor: 4.164

2.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Authors:  Matthias Pfisterer; Hans Peter Brunner-La Rocca; Peter T Buser; Peter Rickenbacher; Patrick Hunziker; Christian Mueller; Raban Jeger; Franziska Bader; Stefan Osswald; Christoph Kaiser
Journal:  J Am Coll Cardiol       Date:  2006-11-02       Impact factor: 24.094

3.  Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Authors:  Yoshinobu Onuma; Patrick W Serruys; Takashi Muramatsu; Shimpei Nakatani; Robert-Jan van Geuns; Bernard de Bruyne; Dariusz Dudek; Evald Christiansen; Pieter C Smits; Bernard Chevalier; Dougal McClean; Jacques Koolen; Stephan Windecker; Robert Whitbourn; Ian Meredith; Hector M Garcia-Garcia; Susan Veldhof; Richard Rapoza; John A Ormiston
Journal:  JACC Cardiovasc Interv       Date:  2014-12       Impact factor: 11.195

4.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.

Authors:  John A Ormiston; Patrick W Serruys; Evelyn Regar; Dariusz Dudek; Leif Thuesen; Mark W I Webster; Yoshinobu Onuma; Hector M Garcia-Garcia; Robert McGreevy; Susan Veldhof
Journal:  Lancet       Date:  2008-03-15       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.